Inogen (INGN) Stock Price, News & Analysis

Company Overview

Inogen, Inc. (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen. These devices are engineered to be lightweight, battery-powered and FAA-approved for in-flight use, addressing both clinical efficacy and user convenience. The company also offers supporting accessories such as batteries, chargers and carrying cases to enhance patient experience and ensure uninterrupted oxygen delivery.

Founded in 2001 and headquartered in Goleta, California, Inogen has obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval for distribution in Europe. The company serves a global customer base through direct-to-consumer sales channels as well as partnerships with home healthcare providers and distributors across North America, Europe and parts of the Asia-Pacific region. Inogen is led by President and Chief Executive Officer Scott Wilkinson, under whose leadership the company has invested in research and development to expand its product portfolio and support emerging digital health initiatives.

Key Stats

• Today's Range: $8.10 to $8.39
• 50-Day Range: $5.87 to $8.12
• 52-Week Range: $5.70 to $12.91
• Volume: 251,175 shs
• Average Volume: 232,119 shs
• Market Capitalization: $219.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Inogen Stock Analysis - MarketRank™

Inogen scored higher than 75% of companies evaluated by MarketBeat, and ranked 230th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Inogen has a consensus price target of $11.00, representing about 35.6% upside from its current price of $8.11.

Amount of Analyst Coverage

Inogen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inogen are expected to grow in the coming year, from ($1.73) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inogen is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inogen is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inogen has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.88% of the outstanding shares of Inogen have been sold short.

Short Interest Ratio / Days to Cover

Inogen has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Inogen has recently increased by 17.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inogen does not currently pay a dividend.

Dividend Growth

Inogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

3.88% of the outstanding shares of Inogen have been sold short.

Short Interest Ratio / Days to Cover

Inogen has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Inogen has recently increased by 17.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.64

News Sentiment

Inogen has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Inogen this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for INGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.46% of the stock of Inogen is held by insiders.

Percentage Held by Institutions

89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INGN Stock Analysis - Frequently Asked Questions

How have INGN shares performed this year?

Inogen's stock was trading at $9.17 at the beginning of 2025. Since then, INGN stock has decreased by 11.6% and is now trading at $8.11.

How were Inogen's earnings last quarter?

Inogen, Inc (NASDAQ:INGN) issued its earnings results on Thursday, August, 7th. The medical technology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The medical technology company had revenue of $92.28 million for the quarter, compared to analyst estimates of $90.40 million. Inogen had a negative net margin of 7.58% and a negative trailing twelve-month return on equity of 13.77%.
Read the conference call transcript.

Who are Inogen's major shareholders?

Inogen's top institutional investors include Kent Lake PR LLC (3.92%), Acadian Asset Management LLC (3.78%), Ameriprise Financial Inc. (3.26%) and Armistice Capital LLC (2.46%).
View institutional ownership trends.

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inogen investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INGN
• CIK: 1294133
• Web: www.inogen.com
• Phone: (805) 562-0500
• Fax: N/A
• Employees: 1,030
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Inogen: $11.00
• High Price Target: $14.00
• Low Price Target: $7.00
• Potential Upside/Downside: +35.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.89 million
• Net Margins: -7.58%
• Pretax Margin: -7.78%
• Return on Equity: -13.77%
• Return on Assets: -8.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $335.70 million
• Price / Sales: 0.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.30 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 27,040,000
• Free Float: 26,645,000
• Market Cap: $219.29 million
• Optionable: Optionable
• Beta: 1.78